RESUMO
BACKGROUND: The effectiveness of a fix-dose salmeterol/fluticasone combination therapy in asthma was previously shown for the original product. The study aim was to evaluate the clinical effectiveness and safety of a second entry DPI - dry powder inhaler (Salflumix Easyhaler) in patients with asthma in everyday clinical practice. PATIENTS AND METHODS: This multicenter Investigator-Initiated Study that enrolled 2,037 adult outpatients with asthma treated with Salflumix Easyhaler, was conducted by 220 pulmonologists across Poland. Asthma control was assessed during 3 visits with 6 ± 2 weeks intervals based on the Asthma Control Test (ACT). In addition, patient Satisfaction with Asthma Treatment Questionnaire (SATQ) and adherence and adverse events (AEs) were monitored. RESULTS: During the observation (86 ± 30 days) the percentage of patients with controlled asthma (ACT 20-25 pts) increased from 35.5% at the first visit to 86.5% at the third visit (p < 0.001). In the subgroup analysis, there were more patients not obtaining asthma control among patients that switched from the treatment with other devices than in naive ones. Global SATQ scores increased from 5.8 ± 0.7 to 6.2 ± 0.6 during the observation. Patients' satisfaction with the use of the Salflumix Easyhaler was high. Adherence exceeded 95%. Eight AEs were reported. CONCLUSIONS: Salflumix Easyhaler is highly effective and well-tolerated by naïve patients with asthma and those switching from another device. In general, patients show good compliance with medical product and are satisfied with the use of this new device, and not reporting difficulties and errors related to its' use. Their physicians' overall perception of Salflumix Easyhaler use is very positive.
Assuntos
Asma , Adulto , Humanos , Asma/tratamento farmacológico , Asma/induzido quimicamente , Fluticasona/efeitos adversos , Xinafoato de Salmeterol , Satisfação do Paciente , Combinação Fluticasona-Salmeterol/uso terapêutico , Resultado do Tratamento , Broncodilatadores/efeitos adversos , Androstadienos/efeitos adversos , AlbuterolRESUMO
BACKGROUND: Fluticasone propionate/salmeterol multidose, dry powder inhaler (MDPI) was the first and only authorized generic inhaled corticosteroid/long-acting beta agonist (ICS/LABA) combination inhaler at the time of this study. This offers the potential for significant prescription cost-savings for both patients and accountable care organizations. The objective of the study was to demonstrate patients' clinical response to generic fluticasone propionate/salmeterol MDPI when switched from one of its brand name competitors. METHODS: The study was approved by the Institutional Review Board at MCPHS University. This was a prospective chart review of a large, multi-center ambulatory care organization in the Greater Boston area. Patients 12 years of age or older who were switched from a brand-name ICS/LABA inhaler to the generic fluticasone/salmeterol MDPI were included in the study. The primary endpoint was worsened asthma control requiring a change in therapy, oral corticosteroid therapy, or hospitalization at or before 12 weeks after the inhaler was switched. RESULTS: In total, 203 patients met inclusion criteria. Of those 203 patients, 35 had a change in therapy due to worsened asthma control (17.2% of patients, 95% CI 12.0% to 22.4%) within 12 weeks. Total projected yearly prescription cost-savings for patients who were switched and remained on the generic inhaler was $581,628. CONCLUSION: Eighty-three percent of patients maintained appropriate asthma control after switching from a brand ICS/LABA inhaler to the generic fluticasone/salmeterol MDPI for 12 weeks. Switching to the generic inhaler resulted in significant prescription cost-savings for the accountable care organization.
Assuntos
Asma , Broncodilatadores , Administração por Inalação , Corticosteroides/uso terapêutico , Assistência Ambulatorial , Asma/tratamento farmacológico , Broncodilatadores/efeitos adversos , Combinação de Medicamentos , Medicamentos Genéricos/uso terapêutico , Fluticasona/efeitos adversos , Combinação Fluticasona-Salmeterol/efeitos adversos , Humanos , Nebulizadores e Vaporizadores , Pós/uso terapêutico , Propionatos/uso terapêutico , Estudos Prospectivos , Xinafoato de Salmeterol/uso terapêuticoRESUMO
INTRODUCTION: Dual bronchodilators are recommended as maintenance treatment for patients with symptomatic COPD in the UK; further evidence is needed to evaluate cost-effectiveness versus monotherapy. Cost-effectiveness of umeclidinium/vilanterol versus umeclidinium and salmeterol from a UK healthcare perspective in patients without exacerbations in the previous year was assessed using post hoc EMAX trial data. METHODS: The validated GALAXY model was populated with baseline characteristics and treatment effects from the non-exacerbating subgroup of the symptomatic EMAX population (COPD assessment test score ≥10) and 2020 UK healthcare and drug costs. Outputs included estimated exacerbation rates, costs, life-years (LYs), and quality-adjusted LYs (QALYs); incremental cost-effectiveness ratio (ICER) was calculated as incremental cost/QALY gained. The base case (probabilistic model) used a 10-year time horizon, assumed no treatment discontinuation, and discounted future costs and QALYs by 3.5% annually. Sensitivity and scenario analyses assessed robustness of model results. RESULTS: Umeclidinium/vilanterol treatment was dominant versus umeclidinium and salmeterol, providing an additional 0.090 LYs (95% range: 0.035, 0.158) and 0.055 QALYs (-0.059, 0.168) with total cost savings of £690 (£231, £1306) versus umeclidinium, and 0.174 LYs (0.076, 0.286) and 0.204 QALYs (0.079, 0.326) with savings of £1336 (£1006, £2032) versus salmeterol. In scenario and sensitivity analyses, umeclidinium/vilanterol was dominant versus umeclidinium except over a 5-year time horizon (more QALYs at higher total cost; ICER=£4/QALY gained) and at the lowest estimate of the St George's Respiratory Questionnaire treatment effect (fewer QALYs at lower total cost; ICER=£12,284/QALY gained); umeclidinium/vilanterol was consistently dominant versus salmeterol. At willingness-to-pay threshold of £20,000/QALY, probability that umeclidinium/vilanterol was cost-effective in this non-exacerbating subgroup was 95% versus umeclidinium and 100% versus salmeterol. CONCLUSION: Based on model predictions from a UK perspective, symptomatic patients with COPD and no exacerbations in the prior year receiving umeclidinium/vilanterol are expected to have better outcomes at lower costs versus umeclidinium and salmeterol.
Assuntos
Doença Pulmonar Obstrutiva Crônica , Administração por Inalação , Álcoois Benzílicos , Broncodilatadores/efeitos adversos , Clorobenzenos , Análise Custo-Benefício , Combinação de Medicamentos , Humanos , Doença Pulmonar Obstrutiva Crônica/diagnóstico , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Quinuclidinas , Xinafoato de Salmeterol/uso terapêutico , Resultado do Tratamento , Reino UnidoRESUMO
BACKGROUND: Chronic obstructive pulmonary disease treatment is informed by randomised controlled trial results, but it is unclear if these findings apply to people excluded from these trials. We used data from the TORCH (TOwards a Revolution in COPD Health) randomised controlled trial to validate non-interventional methods for assessing the clinical effectiveness of chronic obstructive pulmonary disease treatment in the UK Clinical Practice Research Datalink, before applying these methods to the analysis of people who would have been excluded from TORCH. OBJECTIVES: To validate the use of non-interventional Clinical Practice Research Datalink data and methods for estimating chronic obstructive pulmonary disease treatment effects against trial results, and, using validated methods, to determine treatment effects in people who would have been excluded from the TORCH trial. DESIGN: A historical non-interventional cohort design, including validation against randomised controlled trial results. SETTING: The UK Clinical Practice Research Datalink. PARTICIPANTS: People aged ≥ 18 years with chronic obstructive pulmonary disease registered in Clinical Practice Research Datalink GOLD between January 2000 and January 2017. For objective 1, we prepared a cohort that was analogous to the TORCH trial cohort by applying TORCH trial inclusion/exclusion criteria followed by individual matching to TORCH trial participants. For objectives 2 and 3, we prepared cohorts that were analogous to the TORCH trial that, nevertheless, would not have been eligible for the TORCH trial because of age, asthma, comorbidity or mild disease. INTERVENTIONS: The long-acting beta-2 agonist and inhaled corticosteroid combination product Seretide (GlaxoSmithKline plc) [i.e. fluticasone propionate plus salmeterol (FP-SAL)] compared with (1) no FP-SAL exposure or (2) exposure to salmeterol (i.e. the long-acting beta-2 agonist) only. MAIN OUTCOME MEASURES: Exacerbations, mortality, pneumonia and time to treatment change. RESULTS: For objective 1, the exacerbation rate ratio was comparable to that in the TORCH trial for FP-SAL compared with salmeterol (0.85, 95% confidence interval 0.74 to 0.97, vs. TORCH trial 0.88, 95% confidence interval 0.81 to 0.95), but not for FP-SAL compared with no FP-SAL (1.30, 95% confidence interval 1.19 to 1.42, vs. TORCH trial 0.75, 95% confidence interval 0.69 to 0.81). Active comparator results were also consistent with the TORCH trial for mortality (hazard ratio 0.93, 95% confidence interval 0.65 to 1.32, vs. TORCH trial hazard ratio 0.93, 95% confidence interval 0.77 to 1.13) and pneumonia (risk ratio 1.39, 95% confidence interval 1.04 to 1.87, vs. TORCH trial risk ratio 1.47, 95% confidence interval 1.25 to 1.73). For objectives 2 and 3, active comparator results were consistent with the TORCH trial for exacerbations, with the exception of people with milder chronic obstructive pulmonary disease, in whom we observed a stronger protective association (risk ratio 0.56, 95% confidence interval 0.46 to 0.70, vs. TORCH trial risk ratio 0.85, 95% confidence interval 0.74 to 0.97). For the analysis of mortality, we saw a lack of association with being prescribed FP-SAL (vs. being prescribed salmeterol), with the exception of those with prior asthma, for whom we observed an increase in mortality (hazard ratio 1.49, 95% confidence interval 1.21 to 1.85, vs. TORCH trial-analogous HR 0.93, 95% confidence interval 0.64 to 1.32). CONCLUSIONS: Routinely collected electronic health record data can be used to successfully measure chronic obstructive pulmonary disease treatment effects when comparing two treatments, but not for comparisons between active treatment and no treatment. Analyses involving patients who would have been excluded from trials mostly suggests that treatment effects for FP-SAL are similar to trial effects, although further work is needed to characterise a small increased risk of death in those with concomitant asthma. LIMITATIONS: Some of our analyses had small numbers. FUTURE WORK: The differences in treatment effects that we found should be investigated further in other data sets. Currently recommended chronic obstructive pulmonary disease inhaled combination therapy (other than FP-SAL) should also be investigated using these methods. FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 51. See the NIHR Journals Library website for further project information.
Chronic obstructive pulmonary disease affects 3 million people in the UK and is characterised by breathing difficulties that get worse over time, with sudden acute symptoms (exacerbations), possibly requiring hospitalisation. The evidence for use of medicines for treating chronic obstructive pulmonary disease comes from randomised controlled trial results. Randomised controlled trials generally include younger people with severe disease who do not have any other illnesses apart from chronic obstructive pulmonary disease, meaning that the effectiveness of these trials in all people with chronic obstructive pulmonary disease is unknown. Very large databases of anonymous electronic health records captured during NHS consultations can be used to study patients excluded from trials. However, confidence in results from studies using these data can be low because of fears of unaccounted bias, as patients are not randomised to treatment. In this project, we selected a group of patients from a very large electronic health record database called the Clinical Practice Research Datalink who were very similar to participants in a well-known large chronic obstructive pulmonary disease randomised controlled trial [the TORCH (TOwards a Revolution in COPD Health) trial]. When we analysed data from these patients, we found very similar results to the TORCH trial in relation to the reduction of exacerbations, development of pneumonia and time until death, when comparing one chronic obstructive pulmonary disease treatment with another. Having shown that our methods could be trusted to produce valid results when comparing one chronic obstructive pulmonary disease treatment with another, we then went on to analyse patients in the Clinical Practice Research Datalink who would have been excluded from the TORCH trial for the following reasons: aged > 80 years, having asthma as well as chronic obstructive pulmonary disease, or having only mild chronic obstructive pulmonary disease. For exacerbations, we found that, for people with milder chronic obstructive pulmonary disease, one of the treatments we studied seemed to work better than in the trial. For the analysis of mortality, we found that, for people with asthma as well as chronic obstructive pulmonary disease, one of the treatments seemed not to work so well, with more people dying. Future studies are needed in different populations (such as in a database from another country) to confirm these results.
Assuntos
Doença Pulmonar Obstrutiva Crônica , Administração por Inalação , Corticosteroides/uso terapêutico , Estudos de Coortes , Humanos , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Xinafoato de Salmeterol/uso terapêuticoRESUMO
CONTEXTO: A asma é uma doença heterogênea caracterizada por inflamação crônica das vias aéreas, enquanto a DPOC possui caráter não totalmente reversível caracterizada pela limitação crônica ao fluxo aéreo frequentemente associada a uma resposta inflamatória crônica das vias aéreas e do tecido pulmonar. O tratamento da asma e do DPOC visa melhorar a qualidade de vida do paciente por meio do controle dos sintomas e melhora ou estabilização da função pulmonar, além da diminuição das exacerbações na DPOC. O xinafoato de salmeterol, ß2-agonista de longa duração (LABA), é um dos medicamentos utilizado no tratamento dessas enfermidades, todavia sua forma farmacêutica de aerossol bucal 50 mcg não possui registro válido na ANVISA. Existem ainda outros medicamentos da mesma classe LABA disponibilizados no âmbito do SUS, como formoterol e formoterol + budesonida (cápsula ou pó inalante). Sendo assim, a exclusão do salmeterol aerossol bucal 50 mcg não traria prejuízo à população devido à existência de alternativas terapêuticas para essas condições no SUS. TECNOLOGIA: Xinafoato de salmeterol aerossol bucal 50 mcg. JUSTIFICATIVA DA EXCLUSÃO: Ausência de registro válido do xinafoato de salmeterol 50 mcg aerossol bucal na ANVISA. RECOMENDAÇÃO PRELIMINAR DA CONITEC: A matéria teve sua apreciação inicial na 94ª reunião ordinária da Conitec, no dia 03 de fevereiro de 2021. O Plenário deliberou que a matéria fosse disponibilizada em consulta pública com recomendação preliminar favorável à exclusão do salmeterol aerossol bucal para o tratamento da asma e do DPOC, considerando o cancelamento do registro em 2017. CONSULTA PÚBLICA: A Consulta Pública nº 08 foi realizada entre os dias 18/02/2021 e 09/03/2021. Foram recebidas 26 contribuições, sendo seis pelo formulário para contribuições técnico-científicas e 20 pelo formulário para contribuições sobre experiência ou opinião. Dentre as contribuições técnico-científicas, quatro (67%) foram a favor e duas (33%) discordaram da recomendação preliminar da Conitec; dentre as de experiência e opinião, seis (30%) concordaram, três (15%) não concordaram e nem discordaram e onze (55%) discordaram. Embora tenham sido apresentadas contribuições contra a exclusão do salmeterol aerossol, ressalta-se que ele não apresenta registro junto à Anvisa. O SUS disponibiliza outros tratamentos para o controle das condições clínicas, de modo que os pacientes não ficariam desassistidos. Nenhuma das contribuições apresentou novos estudos ou documentos que pudessem agregar novas evidências a esse relatório. RECOMENDAÇÃO FINAL DA CONITEC: Os membros do Plenário da Conitec presentes na 96ª Reunião Ordinária, recomendaram, por unanimidade, a exclusão do salmeterol na apresentação de aerossol bucal (50mcg). Embora tenham sido apresentados relatos positivos acerca deste medicamento, seu registro foi cancelado e deferido pela Anvisa em 2017. Foi assinado o Registro de Deliberação nº 601/2021. DECISÃO: excluir o xinafoato de salmeterol aerossol bucal 50 mcg para tratamento da Asma e da Doença Pulmonar Obstrutiva Crônica (DPOC), conforme Portaria nº 16, publicada no Diário Oficial da União nº 79, seção 1, página 328/329, em 29 de abril de 2021.
Assuntos
Humanos , Asma/tratamento farmacológico , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Recall de Medicamento , Xinafoato de Salmeterol/farmacocinética , Combinação Budesonida e Fumarato de Formoterol/uso terapêutico , Avaliação da Tecnologia Biomédica , Sistema Único de Saúde , Agência Nacional de Vigilância SanitáriaRESUMO
PURPOSE: To characterize subjects with chronic obstructive pulmonary disease (COPD) newly initiated on long-acting muscarinic antagonists (LAMA) or dual LAMA/long-acting ß2-adrenergic agonist (LABA) therapy. DESIGN: This pilot/preliminary analysis was a retrospective crosssectional study of subjects with COPD from the Optum Impact National Managed Care Benchmark Database. METHODOLOGY: Subjects with at least one LAMA prescription in the index period (July 2008-June 2009) were included and stratified by treatment. Data were collected in the year before the index date and included comorbidities, medication use, COPD-related costs, health care resource use, and exacerbations. RESULTS: Of 5,311 eligible subjects, 2,057 initiated LAMA therapy (LAMA cohort) and 191 initiated LAMA+LABA therapy (LAMA+LABA cohort). The Charlson comorbidity index was slightly lower in the LAMA+LABA cohort than the LAMA cohort (mean±SD: 0.63±1.13 vs. 0.66±1.28), but the number of prescriptions was higher (mean±SD: 42.9±23.2 vs. 30.5±27.2). The LAMA+LABA cohort had higher short-acting inhaled ß2 agonist (56.0% vs. 35.7%), oral corticosteroid (37.7% vs. 32.6%), and home oxygen therapy use (14.1% vs. 3.2%) than the LAMA cohort. Total medical costs were greater in the LAMA+LABA cohort than the LAMA cohort (mean±SD: $3,320.40±4085.9 vs. $1,226.20±3602.9), although emergency department ($11.00±66.8 vs. $30.70±259.2) and outpatient visit ($39.60±163.1 vs. $41.70±424.3) costs were lower. Resource use and exacerbation incidence were similar between cohorts. CONCLUSION: In this first look, subjects with COPD initiating LAMA or LAMA+LABA therapy exhibited different clinical and resource use characteristics in the year before treatment. Subjects receiving LAMA+LABA were older, with higher COPD co-medication use, more prescriptions, and associated higher pharmacy costs compared with subjects initiating LAMA. These differences may reflect a higher severity of COPD in those starting LABA+LAMA treatment.
Assuntos
Agonistas Adrenérgicos beta/uso terapêutico , Fumarato de Formoterol/uso terapêutico , Recursos em Saúde/estatística & dados numéricos , Cobertura do Seguro/estatística & dados numéricos , Antagonistas Muscarínicos/uso terapêutico , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Xinafoato de Salmeterol/uso terapêutico , Brometo de Tiotrópio/uso terapêutico , Administração por Inalação , Agonistas Adrenérgicos beta/administração & dosagem , Idoso , Estudos Transversais , Quimioterapia Combinada , Feminino , Fumarato de Formoterol/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Antagonistas Muscarínicos/administração & dosagem , Estudos Retrospectivos , Xinafoato de Salmeterol/administração & dosagem , Brometo de Tiotrópio/administração & dosagem , Resultado do Tratamento , Estados UnidosRESUMO
BACKGROUND: To reduce the number of patients needed or increase the power of hypothesis testing for the parallel groups design, the crossover design has been often employed when one is studying noncurable chronic diseases. This article focuses attention on sample size calculation for testing non-inferiority and equality in frequency data under a 3-treatment 3-period crossover trial. METHOD: Under a multiplicative mixed effects model, this article provides asymptotic sample size calculation procedures for testing non-inferiority of an experimental treatment to a control treatment, as well as for simultaneously testing either of 2 treatments versus a placebo. To improve the performance of these asymptotic procedures in small-sample cases, this article further suggests a simple ad hoc adjustment. RESULTS: On the basis of Monte Carlo simulation, we demonstrate that the asymptotic test procedures proposed here can perform well with respect to Type I error. We find that the asymptotic sample size calculation procedures can generally perform well with respect to power when the resulting sample size is moderate or large. We further find that using the simple ad hoc adjustment can improve the performance of the proposed sample size calculation procedures, which are derived from large-sample theory, in small-sample cases.
Assuntos
Asma/tratamento farmacológico , Broncodilatadores/uso terapêutico , Estudos Cross-Over , Albuterol/uso terapêutico , Ensaios Clínicos como Assunto , Humanos , Método de Monte Carlo , Projetos de Pesquisa , Xinafoato de Salmeterol/uso terapêutico , Tamanho da AmostraRESUMO
OBJECTIVES: To validate outcomes of presently available chronic obstructive pulmonary disease (COPD) cost-effectiveness models against results of two large COPD trials-the 3-year TOwards a Revolution in COPD Health (TORCH) trial and the 4-year Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) trial. METHODS: Participating COPD modeling groups simulated the outcomes for the placebo-treated groups of the TORCH and UPLIFT trials using baseline characteristics of the trial populations as input. Groups then simulated treatment effectiveness by using relative reductions in annual decline in lung function and exacerbation frequency observed in the most intensively treated group compared with placebo as input for the models. Main outcomes were (change in) total/severe exacerbations and mortality. Furthermore, the absolute differences in total exacerbations and quality-adjusted life-years (QALYs) were used to approximate the cost per exacerbation avoided and the cost per QALY gained. RESULT: Of the six participating models, three models reported higher total exacerbation rates than observed in the TORCH trial (1.13/patient-year) (models: 1.22-1.48). Four models reported higher rates than observed in the UPLIFT trial (0.85/patient-year) (models: 1.13-1.52). Two models reported higher mortality rates than in the TORCH trial (15.2%) (models: 20.0% and 30.6%) and the UPLIFT trial (16.3%) (models: 24.8% and 36.0%), whereas one model reported lower rates (9.8% and 12.1%, respectively). Simulation of treatment effectiveness showed that the absolute reduction in total exacerbations, the gain in QALYs, and the cost-effectiveness ratios did not differ from the trials, except for one model. CONCLUSIONS: Although most of the participating COPD cost-effectiveness models reported higher total exacerbation rates than observed in the trials, estimates of the absolute treatment effect and cost-effectiveness ratios do not seem different from the trials in most models.
Assuntos
Broncodilatadores/economia , Análise Custo-Benefício/métodos , Análise Custo-Benefício/normas , Fluticasona/economia , Doença Pulmonar Obstrutiva Crônica/economia , Xinafoato de Salmeterol/economia , Brometo de Tiotrópio/economia , Idoso , Idoso de 80 Anos ou mais , Broncodilatadores/uso terapêutico , Simulação por Computador , Tomada de Decisões , Economia Médica , Feminino , Fluticasona/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Modelos Econométricos , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Doença Pulmonar Obstrutiva Crônica/mortalidade , Anos de Vida Ajustados por Qualidade de Vida , Ensaios Clínicos Controlados Aleatórios como Assunto , Xinafoato de Salmeterol/uso terapêutico , Brometo de Tiotrópio/uso terapêutico , Resultado do TratamentoRESUMO
RATIONALE: Objective adherence to inhaled therapy by patients with chronic obstructive pulmonary disease (COPD) has not been reported. OBJECTIVES: To objectively quantify adherence to preventer Diskus inhaler therapy by patients with COPD with an electronic audio recording device (INCA). METHODS: This was a prospective observational study. On discharge from hospital patients were given a salmeterol/fluticasone inhaler with an INCA device attached. Analysis of this audio quantified the frequency and proficiency of inhaler use. MEASUREMENTS AND MAIN RESULTS: Patients with COPD (n = 244) were recruited. The mean age was 71 years, mean FEV1 was 1.3 L, and 59% had evidence of mild/moderate cognitive impairment. By combining time of use, interval between doses, and critical technique errors, thus incorporating both intentional and unintentional nonadherence, a measure "actual adherence" was calculated. Mean actual adherence was 22.6% of that expected if the doses were taken correctly and on time. Six percent had an actual adherence greater than 80%. Hierarchical clustering found three equally sized well-separated clusters corresponding to distinct patterns. Cluster 1 (34%) had low inhaler use and high error rates. Cluster 2 (25%) had high inhaler use and high error rates. Cluster 3 (36%) had overall good adherence. Poor lung function and comorbidities were predictive of poor technique, whereas age and cognition with poor lung function distinguished those with poor adherence and frequent errors in technique. CONCLUSIONS: These data may inform clinicians in understanding why a prescribed inhaler is not effective and to devise strategies to promote adherence in COPD.
Assuntos
Broncodilatadores/administração & dosagem , Nebulizadores e Vaporizadores , Cooperação do Paciente/estatística & dados numéricos , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Administração por Inalação , Idoso , Broncodilatadores/uso terapêutico , Combinação de Medicamentos , Feminino , Fluticasona/administração & dosagem , Humanos , Masculino , Estudos Prospectivos , Xinafoato de Salmeterol/administração & dosagem , Xinafoato de Salmeterol/uso terapêuticoRESUMO
OBJECTIVE: The objective of this study was to assess the cost effectiveness of the dual bronchodilator indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who had a history of one or no exacerbations in the previous year, in Canada, France, Italy, and Portugal. METHODS: A patient-level simulation was developed to compare the costs and outcomes of IND/GLY versus SFC based on data from the LANTERN trial (NCT01709903). Monte-Carlo simulation methods were employed to follow individual patients over various time horizons. Population and efficacy inputs were derived from the LANTERN trial. Considering the payers' perspective, only direct costs were included. Costs and health outcomes were discounted annually at 3.0 % for all countries. Unit costs were taken from publically available sources with all costs converted to euros (). The cost base year was 2015. Deterministic and probabilistic sensitivity analyses were undertaken to test the robustness of the model results. RESULTS: IND/GLY was found to be the dominant (more effective and less costly) treatment option compared with SFC in all four countries. The use of IND/GLY was associated with mean total cost savings per patient over a lifetime of 6202, 1974, 1611, and 220 in Canada, France, Italy, and Portugal, respectively. Sensitivity analysis showed that exacerbation rates had the largest impact on incremental costs and quality-adjusted life-years (QALYs). The probability of IND/GLY being cost effective was estimated to be >95 % for thresholds above 5000/QALY. CONCLUSION: In patients with moderate to severe COPD, IND/GLY is likely to be a cost-effective treatment alternative compared with SFC.
Assuntos
Broncodilatadores/uso terapêutico , Fluticasona/uso terapêutico , Glicopirrolato/uso terapêutico , Indanos/uso terapêutico , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Quinolonas/uso terapêutico , Xinafoato de Salmeterol/uso terapêutico , Administração por Inalação , Idoso , Broncodilatadores/economia , Canadá , Análise Custo-Benefício , Custos de Medicamentos , Quimioterapia Combinada , Fluticasona/administração & dosagem , Fluticasona/economia , França , Glicopirrolato/administração & dosagem , Glicopirrolato/economia , Custos de Cuidados de Saúde , Humanos , Indanos/administração & dosagem , Indanos/economia , Itália , Masculino , Portugal , Doença Pulmonar Obstrutiva Crônica/economia , Quinolonas/administração & dosagem , Quinolonas/economia , Xinafoato de Salmeterol/administração & dosagem , Xinafoato de Salmeterol/economiaRESUMO
To analyze the frequency of occurrence for an event of interest in a crossover design, we propose a semi-parametric approach. We develop two point estimators and four interval estimators in closed forms for the treatment effect under a random effects multiplicative risk model. Using Monte Carlo simulations, we evaluate these estimators and compare the four interval estimators with the classical interval estimator suggested elsewhere in a variety of situations. We note that the point estimator using the ratio of two arithmetic averages of mean frequencies under a multiplicative risk model can be comparable to the point estimator using the ratio of two geometric averages of mean frequencies. We note that as long as the number of patients per group is large, all the four interval estimators developed here can perform well. We also note that the classical interval estimator derived under the commonly assumed Poisson distribution for the frequency data can be conservative and lose precision if the Poisson distribution assumption is violated. We use a double-blind randomized crossover trial comparing salmeterol with a placebo in exacerbations of asthma to illustrate the practical use of these estimators.
Assuntos
Ensaios Clínicos Controlados Aleatórios como Assunto/estatística & dados numéricos , Agonistas de Receptores Adrenérgicos beta 2/uso terapêutico , Asma/tratamento farmacológico , Bioestatística , Simulação por Computador , Estudos Cross-Over , Método Duplo-Cego , Humanos , Modelos Estatísticos , Método de Monte Carlo , Distribuição de Poisson , Risco , Xinafoato de Salmeterol/uso terapêuticoRESUMO
When the frequency of occurrence for an event of interest follows a Poisson distribution, we develop asymptotic and exact procedures for testing non-equality, non-inferiority and equivalence, as well as asymptotic and exact interval estimators for the ratio of mean frequencies between two treatments under a simple crossover design. Using Monte Carlo simulations, we evaluate the performance of these test procedures and interval estimators in a variety of situations. We note that all asymptotic test procedures developed here can generally perform well with respect to Type I error and can be preferable to the exact test procedure with respect to power if the number of patients per group is moderate or large. We further find that in these cases the asymptotic interval estimator with the logarithmic transformation can be more precise than the exact interval estimator without sacrificing the accuracy with respect to the coverage probability. However, the exact test procedure and exact interval estimator can be of use when the number of patients per group is small. We use a double-blind randomized crossover trial comparing salmeterol with a placebo in exacerbations of asthma to illustrate the practical use of these estimators.
Assuntos
Ensaios Clínicos como Assunto/estatística & dados numéricos , Modelos Estatísticos , Agonistas de Receptores Adrenérgicos beta 2/uso terapêutico , Asma/tratamento farmacológico , Bioestatística , Simulação por Computador , Estudos Cross-Over , Método Duplo-Cego , Humanos , Método de Monte Carlo , Distribuição de Poisson , Ensaios Clínicos Controlados Aleatórios como Assunto/estatística & dados numéricos , Xinafoato de Salmeterol/uso terapêuticoRESUMO
When the frequency of event occurrences follows a Poisson distribution, we develop procedures for testing equality of treatments and interval estimators for the ratio of mean frequencies between treatments under a three-treatment three-period crossover design. Using Monte Carlo simulations, we evaluate the performance of these test procedures and interval estimators in various situations. We note that all test procedures developed here can perform well with respect to Type I error even when the number of patients per group is moderate. We further note that the two weighted-least-squares (WLS) test procedures derived here are generally preferable to the other two commonly used test procedures in the contingency table analysis. We also demonstrate that both interval estimators based on the WLS method and interval estimators based on Mantel-Haenszel (MH) approach can perform well, and are essentially of equal precision with respect to the average length. We use a double-blind randomized three-treatment three-period crossover trial comparing salbutamol and salmeterol with a placebo with respect to the number of exacerbations of asthma to illustrate the use of these test procedures and estimators.
Assuntos
Estudos Cross-Over , Distribuição de Poisson , Ensaios Clínicos Controlados Aleatórios como Assunto/métodos , Albuterol/uso terapêutico , Asma/tratamento farmacológico , Método Duplo-Cego , Feminino , Humanos , Análise dos Mínimos Quadrados , Masculino , Método de Monte Carlo , Xinafoato de Salmeterol/uso terapêuticoRESUMO
CONTEXTO: A Síndrome de Swyer-James-Macleod (SSJM) ou síndrome pulmonar hiperlucente unilateral é uma rara bronquiolite constritiva com obstrução do fluxo de ar e uma diminuição do número e diâmetro dos vasos pulmonares periféricas ipsilaterais. Esta síndrome é caracterizada por hiperlucência unilateral na radiografia de tórax, sendo que a tomografia computadorizada fornece informações adicionais úteis. A doença geralmente se apresenta com dispnéia, diminuição da tolerância ao exercício, tosse, hemoptise, e infecções pulmonares recorrentes. SSJM pode ser confundida com asma ou embolia pulmonar devido a sintomas semelhantes e podem resultar em terapia inapropriada. ). Pode se manifestar de duas formas: assintomática, sendo a maioria diagnosticada na fase adulta, quando o paciente se submete a exames radiológicos de rotina, e a forma sintomática, que é mais encontrada em crianças. Segundo a Classificação Internacional de Doenças 10 (CID-10) é classificada como um tipo de enfisema (J43) dentro do grupo de doenças respiratórias crônicas das vias inferiores. TECNOLOGIA: Glicopirrônio (Seebri®). PERGUNTA: Glicopirrônio é eficaz e seguro para o tratamento da síndrome de Swyer-James-Macleod? EVIDÊNCIAS: Não foram encontrados estudos específicos que avaliassem o uso de glicopirrônio para o tratamento da Síndrome de Swyer-James-Macleod. Foram selecionadas três revisões sistemáticas que avaliaram glicopirrônio para DPOC. No primeiro estudo foi demonstrado que glicopirrônio apresenta resultados semelhantes a outros antagonistas muscarínicos de longa duração (LAMA), como o tiotrópio, para os desfechos de eficácia e qualidade de vida. No segundo estudo, verificou-se que o uso de glicopirrônio em associação com um agonista ß2 de longa duração (indacaterol) é mais eficaz do que o uso desses medicamentos em monoterapia e mais seguro quando comparado a esquemas que utilizam corticoides, quando em monoterapia ou associado a indacaterol. Por fim, o último estudo demonstrou por meio de comparações indiretas que antagonistas muscarínicos apresentam eficácia comparável, especialmente em 12 semanas, a dos agonistas ß2 de longa duração. CONCLUSÕES: A SSJM é uma condição rara e o seu tratamento ainda não é bem estabelecido na literatura. Broncodilatadores são utilizados para tratar os sintomas da doença, dentre os quais está o glicopirrônio. Os resultados das revisões sistemáticas demonstraram que glicopirrônio não apresenta diferenças estatisticamentes significantes para tiotrópio e outros LAMA e para agonistas ß2 de longa duração (LABA), incluindo salmeterol e formoterol que estão disponíveis no SUS para DPOC e asma. Entretanto, o uso associado de glicopirrônio a um agonista ß2 de longa duração (indacaterol) demonstrou melhores resultados do que a monoterapia. Como limitação, ressalta-se que os pacientes avaliados não eram portadores de SSJM, mas de DPOC em geral.
Assuntos
Humanos , Broncodilatadores/uso terapêutico , Antagonistas Colinérgicos/uso terapêutico , Pulmão Hipertransparente/tratamento farmacológico , Análise Custo-Benefício , Fumarato de Formoterol , Xinafoato de Salmeterol , Avaliação da Tecnologia Biomédica , Brometo de TiotrópioRESUMO
Asthma management guidelines emphasize the importance of effective treatment to achieve and maintain control of asthma. However, despite widely available and effective treatments, achieving control of asthma is still an unmet need for many patients. Adding a second bronchodilator with a different mechanism of action for the treatment of uncontrolled asthma can be a suitable therapeutic approach. This review focuses on the role of long-acting muscarinic antagonists, particularly tiotropium, in the treatment of asthma. A number of studies have evaluated the efficacy and safety of tiotropium in asthma patients whose disease is poorly controlled with inhaled corticosteroids (ICSs) with or without long-acting ß2-agonists (LABAs). The effect on several clinical and lung function variables of adding tiotropium to an ICS is greater than doubling the dose of the latter and is not inferior to the addition of a LABA (salmeterol). Studies assessing the role of tiotropium as add-on therapy to ICS combined with a LABA have shown modest but clinically significant and dose-dependent improvements in forced expiratory volume in 1 second, as well as a decrease in the risk of exacerbations. In addition, time to the next episode is longer, particularly in patients who experience severe exacerbations. In conclusion, tiotropium proved noninferior to salmeterol and superior to placebo in patients with moderate-severe asthma who were not adequately controlled using ICSs or ICSs combined with a LABA. The major benefits are the increase in lung function and, in the case of severe asthma, the reduction in the frequency of exacerbations. In patients with asthma, tiotropium is usually well tolerated, and no potential safety signals have been observed.
Assuntos
Asma/tratamento farmacológico , Broncodilatadores/uso terapêutico , Pulmão/efeitos dos fármacos , Antagonistas Muscarínicos/uso terapêutico , Derivados da Escopolamina/uso terapêutico , Corticosteroides/uso terapêutico , Agonistas de Receptores Adrenérgicos beta 2/uso terapêutico , Albuterol/análogos & derivados , Albuterol/uso terapêutico , Asma/diagnóstico , Asma/economia , Asma/fisiopatologia , Broncodilatadores/efeitos adversos , Broncodilatadores/economia , Análise Custo-Benefício , Custos de Medicamentos , Quimioterapia Combinada , Humanos , Pulmão/fisiopatologia , Antagonistas Muscarínicos/efeitos adversos , Antagonistas Muscarínicos/economia , Xinafoato de Salmeterol , Derivados da Escopolamina/efeitos adversos , Derivados da Escopolamina/economia , Índice de Gravidade de Doença , Brometo de Tiotrópio , Resultado do TratamentoRESUMO
BACKGROUND: Indacaterol/glycopyrronium (IND/GLY) is a once-daily inhaled fixed-dose combination of indacaterol (IND), a long-acting ß2-adrenergic agonist (LABA), and glycopyrronium (GLY), a long-acting muscarinic antagonist (LAMA) for use as maintenance treatment to relieve symptoms of chronic obstructive pulmonary disease (COPD) in adults. OBJECTIVE: To determine the economic benefits of IND/GLY compared with the free combination of indacaterol and glycopyrronium (IND + GLY), and with the fixed-dose combination of salmeterol/fluticasone (SFC), in a moderate-to-severe COPD population with low-exacerbation risk. The model-based analysis extrapolated results up to lifetime time horizon and calculated costs per quality-adjusted life year. METHODS: Assuming equal efficacy, a cost-minimisation analysis compared IND/GLY vs IND + GLY using model inputs from the double-blind, randomised SHINE trial. The double-blind, randomised ILLUMINATE and TORCH trials were used to analyse cost-effectiveness versus SFC. To consider ICS-related pneumonia events, published odds ratio comparing an ICS-exposed group to a control group of COPD patients was used. Direct and indirect drug costs as well as drug acquisition costs (in Swedish Krona [SEK]) were derived from published Swedish sources. Cost and effects were discounted with 3%. Uncertainty was assessed by one-way and probabilistic sensitivity analyses (PSA). RESULTS: IND/GLY was cost-saving vs IND + GLY with incremental savings of SEK (EUR) 768 (85), and 3309 (368) per patient over one and five years. IND/GLY was found to be less costly and more effective compared to SFC with cost savings of SEK (EUR) 2744 (303), 8854 (976), 13,938 (1536), 27,495 (3031) and 43,033 (4744) over one, three, five, ten years and lifetime. The PSA indicated that all iterations produced dominant results for IND/GLY. CONCLUSION: IND/GLY is cost-minimising vs IND + GLY and dominates SFC in the maintenance treatment of COPD patients in Sweden. Encouraging dual bronchodilator therapy over an ICS-containing combination results in lower total costs and better outcomes compared to combination therapy including fluticasone in moderate-to-severe COPD patients with low exacerbation risk.
Assuntos
Broncodilatadores/economia , Glicopirrolato/economia , Indanos/economia , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Quinolonas/economia , Idoso , Albuterol/análogos & derivados , Albuterol/economia , Albuterol/uso terapêutico , Androstadienos/economia , Androstadienos/uso terapêutico , Broncodilatadores/administração & dosagem , Broncodilatadores/uso terapêutico , Análise Custo-Benefício , Método Duplo-Cego , Combinação de Medicamentos , Custos de Medicamentos/estatística & dados numéricos , Quimioterapia Combinada , Feminino , Fluticasona , Volume Expiratório Forçado/efeitos dos fármacos , Glicopirrolato/administração & dosagem , Glicopirrolato/uso terapêutico , Humanos , Indanos/administração & dosagem , Indanos/uso terapêutico , Masculino , Pessoa de Meia-Idade , Método de Monte Carlo , Doença Pulmonar Obstrutiva Crônica/economia , Doença Pulmonar Obstrutiva Crônica/fisiopatologia , Quinolonas/administração & dosagem , Quinolonas/uso terapêutico , Xinafoato de Salmeterol , SuéciaRESUMO
G-protein coupled receptors (GPCRs) are involved in a variety of disease processes and comprise major drug targets. However, the complexity of integral membrane proteins such as GPCRs makes the identification of their interacting partners and subsequent drug development challenging. A comprehensive understanding of GPCR protein interaction networks is needed to design effective therapeutic strategies to inhibit these drug targets. Here, we developed a novel split-ubiquitin membrane yeast two-hybrid (MYTH) technology called CHIP-MYTH, which allows the unbiased characterization of interaction partners of full-length GPCRs in a drug-dependent manner. This was achieved by coupling DNA microarray technology to the MYTH approach, which allows a quantitative evaluation of interacting partners of a given integral membrane protein in the presence or absence of drug. As a proof of principle, we applied the CHIP-MYTH approach to the human ß2-adrenergic receptor (ß2AR), a target of interest in the treatment of asthma, chronic obstructive pulmonary disease (COPD), neurological disease, cardiovascular disease, and obesity. A CHIP-MYTH screen was performed in the presence or absence of salmeterol, a long-acting ß2AR-agonist. Our results suggest that ß2AR activation with salmeterol can induce the dissociation of heterotrimeric G-proteins, Gαßγ, into Gα and Gßγ subunits, which in turn activates downstream signaling cascades. Using CHIP-MYTH, we confirmed previously known and identified novel ß2AR interactors involved in GPCR-mediated signaling cascades. Several of these interactions were confirmed in mammalian cells using LUminescence-based Mammalian IntERactome (LUMIER) and co-immunoprecipitation assays. In summary, the CHIP-MYTH approach is ideal for conducting comprehensive protein-protein interactions (PPI) screenings of full-length GPCRs in the presence or absence of drugs, thus providing a valuable tool to further our understanding of GPCR-mediated signaling.
Assuntos
Agonistas de Receptores Adrenérgicos beta 2/farmacologia , Albuterol/análogos & derivados , Mapeamento de Interação de Proteínas/métodos , Mapas de Interação de Proteínas/efeitos dos fármacos , Proteômica/métodos , Receptores Adrenérgicos beta 2/metabolismo , Albuterol/farmacologia , Animais , Células HEK293 , Humanos , Modelos Moleculares , Receptores Acoplados a Proteínas G/metabolismo , Xinafoato de Salmeterol , Transdução de Sinais/efeitos dos fármacos , Técnicas do Sistema de Duplo-Híbrido , Ubiquitina/metabolismoRESUMO
Although studies have established that adding long-acting beta agonists (LABA) to inhaled corticosteroid (ICS) monotherapy among patients with inadequately controlled asthma is associated with better outcomes than increasing ICS dosage, outcomes with ICS versus fixed-dose ICS/LABA combination among patients with recent asthma exacerbation or frequent use of rescue medication are unavailable. This study was designed to compare health-care utilization/costs among patients with recent asthma exacerbation or frequent rescue medication use who received fluticasone propionate (FP) alone versus fixed-dose FP/salmeterol combination (FSC). A retrospective cohort study was conducted using a large health insurance data set. Patients with one or more claims with asthma diagnosis, two or more prescriptions for FSC (250/50- or 100/50-mg formulations) or FP (220- or 110-mg formulations), and one or more asthma exacerbations or five or more short-acting beta agonist (SABA) prescriptions within 1 year before initial receipt of study medications were included. Health-care utilization/costs and controller therapy compliance were compared for patients receiving FSC versus FP using multivariate regression analysis controlling for FP dose and baseline characteristics. A total of 7779 patients met inclusion criteria (5769, FSC, and 2010, FP) with comparable mean follow-up (FSC, 685 days; FP, 670 days; p = 0.151). Controlling for FP dosage and baseline characteristics, FSC patients had lower risks of asthma-related exacerbations, fewer SABAs and systemic corticosteroids, higher costs of asthma medications and total asthma-related health care, and lower total asthma-related health-care costs excluding study medication cost. In asthma patients with recent exacerbation or frequent SABA use, receipt of FSC reduced asthma-related exacerbation risks and rescue medication use versus receipt of FP.
Assuntos
Agonistas de Receptores Adrenérgicos beta 2/uso terapêutico , Albuterol/análogos & derivados , Androstadienos/uso terapêutico , Antialérgicos/uso terapêutico , Asma/tratamento farmacológico , Asma/economia , Custos de Cuidados de Saúde , Adolescente , Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem , Agonistas de Receptores Adrenérgicos beta 2/economia , Albuterol/administração & dosagem , Albuterol/economia , Albuterol/uso terapêutico , Androstadienos/administração & dosagem , Androstadienos/economia , Antialérgicos/administração & dosagem , Antialérgicos/economia , Quimioterapia Combinada , Feminino , Fluticasona , Humanos , Masculino , Cooperação do Paciente , Estudos Retrospectivos , Xinafoato de Salmeterol , Resultado do Tratamento , Adulto JovemRESUMO
INTRODUCTION: Chronic Obstructive Pulmonary Disease (COPD) is a chronic, progressive disease that is not curable. However, there are effective treatments available. In the UK, long-acting bronchodilators are first-line treatments for COPD patients requiring maintenance therapy, and there are several options available. The aim of this study is to establish, from the UK National Health Service (NHS) perspective, the cost-effectiveness profile of indacaterol, the first once-daily long-acting beta2-agonist (LABA), compared with tiotropium and salmeterol, in patients with moderate to severe COPD. In assessing the cost-effectiveness of COPD therapies, this study has the advantage of using real world evidence on the resource use associated with COPD management across the spectrum of the disease. METHODS: A Markov model was developed with four health states following the GOLD classification for severity of airflow limitation. The model time horizon was 3 years, and the cycle length was 3 months. From each state, patients could experience a severe or non-severe exacerbation, move to a different COPD state, remain in the current state or die. Transition probabilities were based on data from the indacaterol clinical trials. The majority of the resource use data was taken from the Optimum Patient Care Research Database (OPCRD), which contains data from over 20,000 COPD patients in England and Scotland. Cost data were taken from UK-based sources and published literature and presented for the cost year 2011. Health-related quality of life was the main outcome of interest and utility data for the COPD states were based on data from the indacaterol clinical trials and disutility due to exacerbations were taken from the literature. Both one way and probabilistic sensitivity analyses were performed to test the robustness of the results. RESULTS: Indacaterol dominated in the comparison with salmeterol producing an incremental QALY gain of 0.008 and cost savings of £110 per patient over a 3-year time horizon. In the comparison with tiotropium over the same time horizon, indacaterol remained the dominant strategy, producing an incremental QALY gain of 0.008 and cost savings of £248 per patient. The one-way sensitivity analysis indicates that the proportion of patients in each of the COPD stages and the mortality rate associated with Very Severe COPD are the variables with the largest impact on the results. The probabilistic sensitivity analyses showed that over 72 % and 89 % of the iterations when compared with salmeterol and tiotropium, respectively, produced dominant results for indacaterol. CONCLUSION: The analyses demonstrate that indacaterol dominates both tiotropium and salmeterol in the base case and is likely to remain cost-effective under a range of assumptions.
Assuntos
Broncodilatadores/administração & dosagem , Broncodilatadores/economia , Custos de Medicamentos/estatística & dados numéricos , Indanos/administração & dosagem , Indanos/economia , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Doença Pulmonar Obstrutiva Crônica/economia , Quinolonas/administração & dosagem , Quinolonas/economia , Idoso , Albuterol/administração & dosagem , Albuterol/análogos & derivados , Albuterol/economia , Análise Custo-Benefício , Esquema de Medicação , Feminino , Humanos , Masculino , Cadeias de Markov , Pessoa de Meia-Idade , Modelos Econômicos , Xinafoato de Salmeterol , Derivados da Escopolamina/administração & dosagem , Derivados da Escopolamina/economia , Brometo de Tiotrópio , Resultado do Tratamento , Reino UnidoRESUMO
BACKGROUND: Asthma affects one in eight children in the UK. National management guidelines have been available for many years but, unlike in adults, studies in children have been few, with their methodologies often based on inappropriate adult models. Sound medical evidence in support of the national guidelines for asthma management in children is lacking. The MASCOT study has been developed to address this need. OBJECTIVES: To determine whether adding salmeterol or montelukast to low-dose inhaled corticosteroids (ICSs) can reduce the number of exacerbations requiring treatment with oral corticosteroids in children with uncontrolled asthma. DESIGN: A randomised, double-blind, placebo-controlled trial with a 4-week run-in period on a fluticasone propionate inhaler (100 µg twice daily) with inhaler technique correction. Patients who met the post run-in period eligibility criteria were randomised in the ratio of 1 : 1 : 1 and were followed for 48 weeks. SETTING: Secondary care hospitals based in England and Scotland with recruitment from primary and secondary care. PARTICIPANTS: Children aged 6-14 years with asthma requiring frequent short-acting beta-2 agonist relief, with symptoms of asthma resulting in nocturnal wakening and/or asthma that has interfered with usual activities. INTERVENTIONS: Three groups were compared: (1) inhaled fluticasone propionate 100 µg twice daily plus placebo tablet once daily; (2) inhaled fluticasone propionate 100 µg and salmeterol 50 µg twice daily (combination inhaler) plus placebo tablet once daily; and (3) inhaled fluticasone propionate 100 µg twice daily plus montelukast 5-mg tablet once daily. MAIN OUTCOME MEASURES: The primary outcome was the number of exacerbations requiring treatment with oral corticosteroids over 48 weeks. Secondary outcome measures included quality of life as measured by the Paediatric Asthma Quality of Life Questionnaire with Standardised Activities [PAQLQ(S)] and the Paediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ); time from randomisation to first exacerbation requiring treatment with a short course of oral corticosteroids; school attendance; hospital admissions; amount of rescue beta-2 agonist therapy prescribed; time from randomisation to treatment withdrawal (because of lack of efficacy or side effects); lung function at 48 weeks (as assessed by spirometry); cost-effectiveness; adverse events. RESULTS: The study was closed prematurely because of poor recruitment and the target sample size of 450 was not achieved. In total, 898 children were screened to enter the trial, 166 were registered for the 4-week run-in period and 63 were randomised (group 1: 19, group 2: 23, group 3: 21), with 38 contributing data for the primary outcome analysis. There were no significant differences between groups for any of the outcomes. Adverse events were similar between the groups except for nervous system disorders, which were more frequently reported on fluticasone plus montelukast. CONCLUSIONS: Based on the results of the MASCOT study it is not possible to conclude whether adding salmeterol or montelukast to ICSs can reduce the number of exacerbations requiring treatment with oral corticosteroids in children with uncontrolled asthma. TRIAL REGISTRATION: Current Controlled Trials ISRCTN03556343. FUNDING: This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 17, No. 4. See the HTA programme website for further project information.